Quality of Life After Hysterectomy (AdenoQOL)

Condition(s) studied

Investigational drug(s) / intervention(s)

Hysterectomy: Elective procedure with hysterectomy due to benign gynecological condition

Study summary

Adenomyosis is a disease where ectopic endometrial-like glands affect the muscular wall of the uterus. About 70% of women affected by adenomyosis suffer from dysmenorrhea and menorrhagia. A levonorgestrel-releasing intrauterine device (LNG-IUD) is the first-choice treatment of adenomyosis, but is not always sufficiently effective in all women. Those women often end up removing the uterus (hysterectomy).

Hysterectomy is clinically regarded to be an efficient and final treatment of adenomyosis, but pelvic pain may also prevail after removal of the uterus. This study aimes to investigate the short - and long-term impact of hysterectomy on quality of life (QOL) and sexual function in women with adenomyosis, and further to evaluate if there is any difference compared to women that are removing their uterus due to other benign gynecological conditions.

Eligibility

Primary outcome measure(s)

• The impact of hysterectomy on health related quality of life assessed by SF-36 sub scale bodily pain — 1 year
  The Short Form Health Survey (SF-36) measures eight sub scales including bodily pain (BP) which in this study is used as primary outcome. The scales ranges from 0-100, a higher score indicates a better quality of life.

Trial sites (1)

More Oslo University Hospital trials in Norway

Other trials for the same condition